Fresenius SE & Co. KGaA, commonly referred to as Fresenius, is a global healthcare group headquartered in Bad Homburg, Germany. Founded in 1912, the company has established itself as a leader in the healthcare industry, with significant operations across Europe, North America, and Asia. Fresenius operates primarily in the fields of dialysis, hospital management, and medical devices, providing innovative solutions that enhance patient care.
The company’s core offerings include dialysis products and services through Fresenius Medical Care, as well as pharmaceuticals and clinical nutrition via Fresenius Kabi. Known for its commitment to quality and patient-centric solutions, Fresenius has achieved notable milestones, including being a key player in the global dialysis market. With a strong market position and a reputation for excellence, Fresenius continues to drive advancements in healthcare, making a meaningful impact on patients' lives worldwide.
+50 vs industry average
Fresenius’s score of 77 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Fresenius?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medical Device Manufacturing has typical carbon intensity
Industry performance
The Medical Device Manufacturing industry has reduced its overall emissions by 18% since 2019
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Fresenius's reported carbon emissions
In 2025, Fresenius reported total carbon emissions of approximately 4.26 billion kg CO2e, comprising 317,448,000 kg CO2e from Scope 1, 170,000,000 kg CO2e from Scope 2, and 3,771,052,000 kg CO2e from Scope 3 emissions. This data reflects a commitment to transparency and accountability in their climate impact. Fresenius has set ambitious climate targets, aiming for a 50% reduction in absolute Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. Additionally, the company is striving for climate neutrality by 2040. For Scope 3 emissions, Fresenius plans to achieve net zero by 2050, targeting a gross reduction of at least 90% of avoidable greenhouse gas emissions. The emissions data is sourced directly from Fresenius SE & Co. KGaA, ensuring accuracy and reliability. The company is actively working towards these goals, demonstrating a strong commitment to sustainability and climate action within the healthcare sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Fresenius’s Climate Goals (2030 & 2050)
9 goals2030
50% reduction in Scope 2
Reduction by 50% by 2030: By 2030, Fresenius aims to reduce all Scope 1 and Scope 2 emissions in absolute value by 50% (gross), compared to…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 9 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
10 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Fresenius
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project